{"id":58507,"date":"2023-12-01T13:05:57","date_gmt":"2023-12-01T12:05:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/study-finds-nurse-practitioners-and-physician-assistants-would-alter-patient-care-decisions-based-on-decisiondx-melanoma-test-results\/"},"modified":"2023-12-01T13:05:57","modified_gmt":"2023-12-01T12:05:57","slug":"study-finds-nurse-practitioners-and-physician-assistants-would-alter-patient-care-decisions-based-on-decisiondx-melanoma-test-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/study-finds-nurse-practitioners-and-physician-assistants-would-alter-patient-care-decisions-based-on-decisiondx-melanoma-test-results\/","title":{"rendered":"Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx\u00ae-Melanoma Test Results"},"content":{"rendered":"
\n

\nIn a survey of nurse practitioners and physician assistants (NPs\/PAs), 82.4% of respondents who use DecisionDx-Melanoma in clinical practice stated that a high-risk test result in a thin melanoma tumor (\u22641mm) would impact their patient treatment plan; similarly, 81.3% of test users would alter treatment plans based on a high-risk test result in Stage 1 tumors<\/i><\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CSTL<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO)<\/i> that assessed the viewpoints of NPs\/PAs toward the clinical use of DecisionDx\u00ae-Melanoma in patients diagnosed with cutaneous melanoma. The study found that more than 90% of the NPs\/PAs who completed a survey about DecisionDx-Melanoma believe that prognostic (i.e., risk-stratification) information about a patient\u2019s melanoma is valuable and improves patient care. The study is available here<\/a>.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cHistorically, patients with thin or Stage 1 tumors would be considered to be at the lowest risk of metastasis or recurrence, based on traditional staging factors alone,\u201d said Renata Block, MMS, PA-C, first study author and board-certified physician assistant at Advanced Dermatology & Aesthetic Medicine, LLC in Chicago. \u201cAs the study data affirmed, the personalized, clinically actionable results provided by DecisionDx-Melanoma can significantly impact the treatment plans of patients with melanoma, particularly in the ‘low-risk’ patient population when their test results indicate aggressive tumor biology that would place them at a higher risk of a poor outcome.\u201d<\/p>\n

\nStudy methods and findings:<\/i><\/p>\n